ANI PHARMACEUTICALS INC (ANIP)

Insider Trading Filed: 2026-04-13

The reporting person, Meredith Cook, is an officer of ANI Pharmaceuticals, Inc. (ticker: ANIP) and has sold 500 shares of the company's common stock at $77.95 per share.
The sale was made pursuant to a pre-arranged 10b5-1 trading plan, indicating it was part of a planned transaction rather than an ad hoc sale.
Following the reported transaction, the reporting person continues to hold 78,890 shares of the company's common stock, suggesting a still significant ownership stake.

Current Report Filed: 2026-04-07

ANI Pharmaceuticals has dismissed its independent registered public accounting firm, EisnerAmper LLP, and appointed Ernst & Young LLP as the new firm effective April 1, 2026. This change in auditor could signal a shift in the company's financial reporting and oversight.
The filing notes that there were no disagreements or reportable events between ANI Pharmaceuticals and the former auditor, EisnerAmper, during the prior fiscal years. This suggests the change was not due to any significant accounting issues.
The company did not consult with the new auditor, Ernst & Young, regarding any matters prior to their appointment. This is typical for a change in accounting firms and indicates a clean transition.

Insider Trading Filed: 2026-03-10

The reporting person, Stephen P. Carey, who serves as the SVP and CFO of ANI Pharmaceuticals, Inc., disposed of 5,150 shares of common stock through a share withholding transaction for tax purposes.
This transaction occurred on March 7, 2026, in connection with the vesting of 11,292 shares of restricted stock, which was previously reported.
The reported transaction suggests that the insider may be taking some gains or liquidity, but the overall ownership position remains substantial at 180,393 shares.

Insider Trading Filed: 2026-03-10

Insider Krista Davis, SVP and Chief HR Officer, sold a total of 6,572 shares of ANI Pharmaceuticals stock over two days on March 6 and March 9, 2026 at an average price of $74.57.
The sale was made pursuant to a pre-planned Rule 10b5-1 trading plan, indicating the transactions were not opportunistic.
Davis still holds 51,946 shares of ANI Pharmaceuticals stock directly following the reported transactions, suggesting continued confidence in the company.

Insider Trading Filed: 2026-03-10

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, disposed of 3,314 shares of common stock through a stock withholding transaction to cover tax obligations related to the vesting of restricted stock.
This insider transaction represents a small portion (4%) of Gutwerg's total beneficial ownership of 81,468 shares, indicating a limited sell-off.
The transaction was executed in accordance with Rule 10b5-1, suggesting it was part of a pre-planned trading arrangement and not an opportunistic sale.

Insider Trading Filed: 2026-03-10

Nikhil Lalwani, the President and CEO of ANI Pharmaceuticals, has disposed of 17,060 shares of common stock through a stock withholding transaction to cover tax obligations associated with the vesting of 33,352 shares of restricted stock.
Following the transaction, Lalwani still beneficially owns 404,889 shares of ANI Pharmaceuticals, indicating he continues to have a substantial stake in the company.
The transaction appears to be a routine tax withholding event and does not necessarily signal any major changes in Lalwani's outlook or the company's performance.

Insider Trading Filed: 2026-03-10

Insider Christopher Mutz sold a total of 5,723 shares of ANI Pharmaceuticals (ANIP) stock on March 6, 7, and 9, 2026 at weighted average prices ranging from $74.04 to $74.22 per share.
The insider sales were conducted pursuant to a pre-planned Rule 10b5-1 trading plan, indicating a degree of intention behind the transactions.
Mutz's beneficial ownership of ANIP stock decreased from 101,387 shares to 94,471 shares, representing a 6.8% reduction in his holdings.

Insider Trading Filed: 2026-01-14

Meredith W. Cook, the Senior Vice President, General Counsel, and Secretary of ANI Pharmaceuticals, Inc., sold 500 shares of the company's common stock at an average price of $84.33 per share.
This transaction was made pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on September 15, 2025.
Following the reported transaction, Meredith W. Cook continues to beneficially own 74,374 shares of ANI Pharmaceuticals' common stock.

Current Report Filed: 2026-01-12

ANI Pharmaceuticals has announced preliminary unaudited financial results for Q4 and FY 2025, providing investors with an early look at the company's performance.
The company has also provided initial financial guidance for 2026, which could signal management's confidence in the business outlook.
The CEO's upcoming presentation at the J.P. Morgan Healthcare Conference suggests the company may have important updates or developments to share with the investment community.

Important Information